Kharasch E D, Hankins D C, Thummel K E
Department of Anesthesiology, University of Washington, Seattle, 98195.
Anesthesiology. 1995 Mar;82(3):689-99. doi: 10.1097/00000542-199503000-00011.
Methoxyflurane nephrotoxicity is mediated by cytochrome P450-catalyzed metabolism to toxic metabolites. It is historically accepted that one of the metabolites, fluoride, is the nephrotoxin, and that methoxyflurane nephrotoxicity is caused by plasma fluoride concentrations in excess of 50 microM. Sevoflurane also is metabolized to fluoride ion, and plasma concentrations may exceed 50 microM, yet sevoflurane nephrotoxicity has not been observed. It is possible that in situ renal metabolism of methoxyflurane, rather than hepatic metabolism, is a critical event leading to nephrotoxicity. We tested whether there was a metabolic basis for this hypothesis by examining the relative rates of methoxyflurane and sevoflurane defluorination by human kidney microsomes.
Microsomes and cytosol were prepared from kidneys of organ donors. Methoxyflurane and sevoflurane metabolism were measured with a fluoride-selective electrode. Human cytochrome P450 isoforms contributing to renal anesthetic metabolism were identified by using isoform-selective inhibitors and by Western blot analysis of renal P450s in conjunction with metabolism by individual P450s expressed from a human hepatic complementary deoxyribonucleic acid library.
Sevoflurane and methoxyflurane did undergo defluorination by human kidney microsomes. Fluoride production was dependent on time, reduced nicotinamide adenine dinucleotide phosphate, protein concentration, and anesthetic concentration. In seven human kidneys studied, enzymatic sevoflurane defluorination was minima, whereas methoxyflurane defluorination rates were substantially greater and exhibited large interindividual variability. Kidney cytosol did not catalyze anesthetic defluorination. Chemical inhibitors of the P450 isoforms 2E1, 2A6, and 3A diminished methoxyflurane and sevoflurane defluorination. Complementary deoxyribonucleic acid-expressed P450s 2E1, 2A6, and 3A4 catalyzed methoxyflurane and sevoflurane metabolism, in diminishing order of activity. These three P450s catalyzed the defluorination of methoxyflurane three to ten times faster than they did that of sevoflurane. Expressed P450 2B6 also catalyzed methoxyflurane defluorination, but 2B6 appeared not to contribute to renal microsomal methoxyflurane defluorination because the P450 2B6-selective inhibitor had no effect.
Human kidney microsomes metabolize methoxyflurane, and to a much lesser extent sevoflurane, to fluoride ion. P450s 2E1 and/or 2A6 and P450 3A are implicated in the defluorination. If intrarenally generated fluoride or other metabolites are nephrotoxic, then renal metabolism may contribute to methoxyflurane nephrotoxicity. The relative paucity of renal sevoflurane defluorination may explain the absence of clinical sevoflurane nephrotoxicity to date, despite plasma fluoride concentrations that may exceed 50 microM.
甲氧氟烷的肾毒性是由细胞色素P450催化代谢生成毒性代谢产物介导的。传统观点认为,其中一种代谢产物氟化物是肾毒素,且甲氧氟烷肾毒性是由血浆氟化物浓度超过50微摩尔/升所致。七氟烷也会代谢生成氟离子,血浆浓度可能超过50微摩尔/升,但尚未观察到七氟烷肾毒性。甲氧氟烷的肾脏原位代谢而非肝脏代谢,可能是导致肾毒性的关键因素。我们通过检测人肾微粒体对甲氧氟烷和七氟烷的脱氟相对速率,来验证这一假说是否存在代谢基础。
从器官捐献者的肾脏中制备微粒体和胞质溶胶。用氟离子选择性电极测定甲氧氟烷和七氟烷的代谢情况。通过使用同工型选择性抑制剂以及对肾细胞色素P450进行蛋白质印迹分析,并结合人肝脏互补脱氧核糖核酸文库中表达的单个细胞色素P450的代谢情况,来鉴定参与肾脏麻醉药代谢的人细胞色素P450同工型。
人肾微粒体确实能使七氟烷和甲氧氟烷发生脱氟反应。氟化物生成量取决于时间、还原型烟酰胺腺嘌呤二核苷酸磷酸、蛋白质浓度和麻醉药浓度。在研究的7个供体肾脏中,七氟烷的酶促脱氟作用极小,而甲氧氟烷的脱氟速率则大得多,且个体间差异很大。肾胞质溶胶不能催化麻醉药脱氟。细胞色素P450同工型2E1、2A6和3A的化学抑制剂可减少甲氧氟烷和七氟烷的脱氟。互补脱氧核糖核酸表达的细胞色素P450 2E1、2A6和3A4可催化甲氧氟烷和七氟烷的代谢,活性依次降低。这三种细胞色素P450催化甲氧氟烷脱氟的速度比催化七氟烷脱氟的速度快3至10倍。表达的细胞色素P450 2B6也可催化甲氧氟烷脱氟,但由于细胞色素P450 2B6选择性抑制剂无效,所以细胞色素P450 2B6似乎对肾微粒体甲氧氟烷脱氟没有作用。
人肾微粒体可将甲氧氟烷代谢为氟离子,而将七氟烷代谢为氟离子的程度要小得多。细胞色素P450 2E1和/或2A6以及细胞色素P450 3A参与了脱氟反应。如果肾脏内生成的氟化物或其他代谢产物具有肾毒性,那么肾脏代谢可能会导致甲氧氟烷肾毒性。尽管血浆氟化物浓度可能超过50微摩尔/升,但肾脏对七氟烷脱氟相对较少,这可能解释了迄今为止临床上未出现七氟烷肾毒性的原因。